Prescription drug · ANDA
Anastrozole (anastrozole tablets) NDC 68071-3999
Anastrozole 1 mg/1 · Tablet · Oral · NuCare Pharmaceuticals, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 68071-3999-3 | 68071399903 | 30 TABLET in 1 BOTTLE (68071-3999-3)Marketed from May 7, 2026 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Anastrozole
- Generic name (nonproprietary)
- anastrozole tablets
- Active ingredients
- Anastrozole — 1 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- NuCare Pharmaceuticals, Inc.
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 206037
- Marketing start
- Listing expires
- Other FDA classes
- Aromatase Inhibitors (Mechanism)
- Identifiers
- Product ID 68071-3999_513e8b37-627e-1e3e-e063-6294a90a9b44SPL ID 513e8b37-627e-1e3e-e063-6294a90a9b44SPL set ID 513e8413-af48-4acc-e063-6294a90a24b4RxCUI 199224UNII 2Z07MYW1AZ
- Pharmacologic class
- Aromatase Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N468071399903followed by a unit qualifier and the quantityPackage 68071-3999-03. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breas…
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 206037
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Anastrozole | Anastrozole 1 mg/1 | TabletOral | Direct_Rx | 72189-682 |
| Anastrozole | Anastrozole 1 mg/1 | TabletOral | Chartwell RX, LLC | 62135-490 |
| Anastrozoleanastrozole tablets | Anastrozole 1 mg/1 | TabletOral | Proficient Rx LP | 82804-162 |
| Anastrozoleanastrozole tablets | Anastrozole 1 mg/1 | TabletOral | Upsher-Smith Laboratories, LLC | 24979-725 |
| Anastrozoleanastrozole tablets | Anastrozole 1 mg/1 | TabletOral | Avet Pharmaceuticals Inc | 23155-857 |
| Anastrozoleanastrozole tablets | Anastrozole 1 mg/1 | TabletOral | ASCLEMED USA INC. | 87063-224 |
| Anastrozoleanastrozole tablets | Anastrozole 1 mg/1 | TabletOral | Yiling Pharmaceutical, Inc. | 69117-0003 |